Solid Dosage
With our comprehensive portfolio of oral solid dosage solutions, we can supply full process lines with containment interfaces for process steps from API and excipient dispensing, dry milling, powder collection and blending through to tableting and coating.
With an increasing emphasis on both operator safety and product protection, the commercial-scale production of oncology drugs, hormonal products and/or other highly potent compounds has been put under the pharmaceutical spotlight in recent years.
Eliminating the need for cumbersome isolation suits to prevent operators being exposed to hazardous substance and avoid cross-contamination with other products manufactured in the same facility, GEA’s approach is to use containment interfaces (the BUCK® MC high-containment range and disposable Hicoflex® products) to ensure compliance with global regulatory cGMP requirements.
Experts in contained material handling, closed product processing, gentle product treatment, the efficient recovery of active ingredients and reliable scale-up, we supply modules, components and fully integrated batch and continuous lines for the production of oncology drugs and other therapeutic agents that deliver increased yields and reduced cycle times.
From R&D-scale and standalone production equipment to contained production lines, we understand the absolute importance of preventing cross-contamination in the production area, protecting both people and products, and working within Real Daily Intake (RDI) and Acceptable Daily Intake (ADI) limits with up to occupational exposure band (OEB) 5 drugs.
GEA has a wealth of expertise and an unparalleled depth of experience in the field of containment. The company not only offers a comprehensive range of robust and compliant containment products, it also boasts unrivaled experience in identifying the most appropriate solution and a thorough understanding of containment risk analysis.
يتم عرض 4 من 25
Contained Materials Handling solutions for Primary and Secondary Pharmaceuticals and Healthcare. With extensive experience within the generics sector, supply a wide range of technologies and equipment that improve and enhance the efficiency and performance of Oral Solid Dosage production.
The ConsiGma® DC for direct compression is the latest expansion of GEA's continuous portfolio for cost effective, compact, high yield manufacturing systems. It offers a robust and flexible manufacturing method for a wide range of products.
Continuous Processing is becoming more and more important in the pharmaceutical industry. GEA takes the lead in introducing this innovative technology with ConsiGma® - continuous high-shear granulation and drying lines.
At GEA, we believe that continuous processing improves the quality of pharmaceutical end products: by focusing on quality during the whole product lifecycle, not just “tested in” quality; and by understanding the capability of your processes, managing sources of variability and decreasing any associated risks.
يعد تقليل النفايات أمرًا مهمًا بالنسبة لنا في GEA، ومن خلال الاستفادة من قوة تكنولوجيا التجفيف بالتجميد، يمكننا تحويل فائض الطعام إلى منتجات قيِّمة وطويلة الأمد - مما يساعد على تقليل النفايات وإطالة العمر الافتراضي للمنتجات وبناء إمدادات غذائية أكثر مرونة للأجيال القادمة.
كان خبراء البحث والتطوير في GEA على قدر التحدي عندما طرحت Pulmuone، وهي شركة كورية جنوبية متخصصة في إنتاج الأغذية النباتية، تحديًا لـ GEA يتمثل في إضفاء لمسة حديثة على النودلز الكورية الباردة التقليدية ذات القوام الواضح في الفم (النينجميون). وساعدوا في تطوير ما أصبح الآن نجاحًا تجاريًا يتم إنتاجه باستخدام كميات أقل من المياه والكهرباء مقارنةً بالطرق المستخدمة سابقًا. وتتوافق النتيجة أيضًا مع الأصول التقليدية للطبق بالإضافة إلى جذور Pulmuone في الصحة والعافية والاستدامة.